Aligos Therapeutics extended its headquarters Lease through March 31, 2034, with monthly base rent reaching $5.716 per rentable square foot in the final lease year. The agreement matters to investors because it establishes future occupancy costs, provides rent abatement from April 1, 2027 to January 31, 2028, and creates specified termination options.
Key Highlights
- The First Amendment extends the headquarters lease from March 31, 2027 to March 31, 2034.
- Rent abatement applies from April 1, 2027 to January 31, 2028, subject to the lease remaining free of material default.
- Aligos can terminate the lease as of March 31, 2031 by paying $2,476,429.22 under the stated option.
The First Amendment extends Aligos Therapeutics, Inc. (NASDAQ: ALGS)’s headquarters lease at One Corporate Drive in South San Francisco through March 31, 2034. Monthly base rent per rentable square foot begins at $4.650 from April 1, 2027 to March 31, 2028.
Lease Schedule Adds Rent Relief and Exit Rights
The agreement requires Aligos Therapeutics to pay a specified percentage of certain landlord-paid expenses. Aligos may end the lease as of March 31, 2031 by delivering written notice on or before March 31, 2030 and paying $2,476,429.22 by the termination date. The amendment revises the existing extension option to one seven-year option for the period immediately following the extended lease term. The Lease is dated June 21, 2018, and the amendment was entered into with Britannia Biotech Gateway Limited Partnership.
FAQs
Q: What is Aligos Therapeutics’ new headquarters lease term?
A: Aligos Therapeutics’ amended headquarters lease runs through March 31, 2034. The premises are at One Corporate Drive, South San Francisco.
Q: How much can Aligos pay to terminate the lease in 2031?
A: Aligos can terminate the lease as of March 31, 2031 by paying $2,476,429.22. Written notice must be delivered on or before March 31, 2030.
Q: When does Aligos’ rent abatement apply?
A: The rent abatement applies for ten months, from April 1, 2027 through January 31, 2028. It is available provided there is no material default under the Lease.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.